Trials / Recruiting
RecruitingNCT07228078
Open-Label Extension Protocol to SNK01-AD01 Study
An Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Alzheimer's Disease (Study SNK01-AD02)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- NKGen Biotech, Inc. · Industry
- Sex
- All
- Age
- 40 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Open-Label Extension Protocol to SNK01-AD01 Study
Detailed description
Open-label extension study to assess long-term safety and tolerability of SNK01 administered as an intravenous (IV) infusion every 3 weeks in participants with Alzheimer's Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SNK01 | SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug |
Timeline
- Start date
- 2025-06-30
- Primary completion
- 2028-04-01
- Completion
- 2028-04-01
- First posted
- 2025-11-13
- Last updated
- 2025-11-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07228078. Inclusion in this directory is not an endorsement.